Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entera Bio (ENTX) Share-based Compensation (2021 - 2025)

Entera Bio has reported Share-based Compensation over the past 5 years, most recently at $710000.0 for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation rose 25.44% year-over-year to $710000.0, compared with a TTM value of $2.8 million through Dec 2025, up 7.59%, and an annual FY2025 reading of $2.8 million, up 7.59% over the prior year.
  • Share-based Compensation came in at $710000.0 for Q4 2025, down from $927000.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $964000.0 in Q1 2022 to a low of $110000.0 in Q3 2022.
  • Median Share-based Compensation over the past 5 years was $527000.0 (2021), compared with a mean of $555150.0.
  • The sharpest move saw Share-based Compensation crashed 82.48% in 2022, then surged 248.18% in 2023.
  • Over 5 years, Share-based Compensation stood at $368000.0 in 2021, then increased by 29.62% to $477000.0 in 2022, then crashed by 33.33% to $318000.0 in 2023, then soared by 77.99% to $566000.0 in 2024, then increased by 25.44% to $710000.0 in 2025.
  • Per Business Quant, the three most recent readings for ENTX's Share-based Compensation are $710000.0 (Q4 2025), $927000.0 (Q3 2025), and $509000.0 (Q2 2025).